American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical…

By D. Saslow, D. Solomon, Herschel W. Lawson, M. Killackey, Shalini L. Kulasingam, J. Cain, Francisco A. R. Garcia, A. Moriarty, Alan Waxman, D. Wilbur and 9 more. American Journal of Clinical Pathology, 2012

2,380 citations recorded by the source corpus.

Subfields: Plant Science

View Paper: https://www.semanticscholar.org/paper/c343e87fa737c76f4999b99455435070fc9bb894

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. R. Siegel
2. K. Miller
3. A. Jemal
4. C. DeSantis
5. Robert A. Smith
6. Le Lu
7. Kehinde Okunade
8. A. Moscicki

Citations in the corpus

• DeepPap: Deep Convolutional Networks for Cervical Cell Classification (2017, background): “However, populationwide screening is still unavailable in underdeveloped countries [2], partly due to the complexity and tedious nature of manually screening abnormal cells from a cervical cytology specimen [3].”
• 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. (2013, methodology): “Co-testing with cytology and HPV testing at 5-year intervals is now the preferred or acceptable strategy for cervical cancer screening for women aged 30Y64 years (10, 11).”
• Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels (2013, background): “105, Issue 3 | February 6, 2013 196 Articles | JNCI treatment of abnormal lesions (31,87,88).”
• Human papillomavirus and cervical cancer. (2019, positive): “Several other studies, such as the ATHENA study [45], have also examined and confirmed the role of HPV”
• 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors (2020, positive): “Rationale: Using the principle of equal management for equal risk, the 3-year return Clinical Action Threshold corresponds to the 5-year CIN 3+ risk after negative cervical cytology in the general population, for whom national guidelines recommend a 3-year return.(13,14) Estimated 5-year CIN 3+ risk”
• Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening (2018, background): “Additional details for managing cervical cancer screening in women who have abnormal findings or are at different risk are detailed in the guideline.(8,33)”
• Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities (2016, background): “(Table 8).118 Vaccinated women need to continue to receive recommended cervical cancer screening, because these vaccines only target the most common strains of HPV, and they also do not provide protection for those women who are already infected with HPV.119,120”
• Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement (2012, methodology): “Current guidelines define adequate screening as 3 consecutive negative cytology results or 2 consecutive negative HPV results within 10 years before cessation of screening, with the most recent test performed within 5 years (7).”